Protein-maxxing, GLP-1s have US farmers betting on peas and lentils

Rising demand for protein-rich foods is boosting pea and lentil growers, with one farmer estimating a loss of $35 per acre for wheat versus an $8 profit per acre for lentils. U.S. yellow pea plantings are up 55% over 15 years, while exports fell 81% from 2021 to 2025, indicating more domestic consumption. The article also highlights lower input costs for pulses and growing corporate investment in pea-protein products, though nutrition experts question the sustainability of the protein craze.

Analysis

The market is still underestimating how sticky the pea/lentil shift can be once it enters farm rotation economics rather than “trend” economics. For ADM, this is a cleaner story than a simple protein-demand call: lower fertilizer intensity and better soil economics make pulses the rational marginal acre when wheat margins are negative, which should support sustained sourcing volumes even if retail protein enthusiasm cools. GIS benefits indirectly because branded food companies can keep pushing protein claims without needing a full step-change in willingness-to-pay; however, the real upside accrues to ingredient suppliers and processors, not finished-food brands.

The second-order dynamic is that domestic pulse demand may continue absorbing supply even if export channels stay weak, which creates a more stable North American pricing base than headline trade data suggests. That helps ADM’s ingredient mix and processing utilization, while also pressuring smaller commodity crop suppliers that rely on acreage returning to grains; if the rotation stays tilted to pulses for another 1-2 seasons, it could structurally cap wheat and feed-grain acres in the northern Plains. The hidden risk is that protein demand can decouple from actual end-consumer repeat purchase behavior—if the current protein wave is influencer-driven, ingredient demand may be stronger than branded shelf velocity for 2-4 quarters before normalization.

The contrarian view is that this is less a new secular growth market than a substitution cycle within a constrained farm economy. If crop prices recover or fertilizer/diesel costs fall, some of the acreage incentive reverses quickly, but the more immediate catalyst is margin repair in pulse processing and protein-isolate supply chains over the next 6-12 months. The main tail risk for ADM is overcapacity if too much capital follows the trend; the main tail risk for GIS is that it gets stuck with a premium valuation for a protein narrative it cannot fully monetize.

For now, the trade is to own the infrastructure behind the protein theme rather than the consumer wrapper. The setup is better on a 6-12 month horizon than on a 2-4 week tactical horizon, because acreage decisions and foodformulation cycles both take time to show up in earnings. If protein claims keep expanding, ADM should see the most durable earnings leverage; if the fad fades, ADM still retains the ag-processing upside, while GIS likely loses multiple support.

Key Decisions for Investors

• Go long ADM on a 6-12 month horizon; the best risk/reward is from improved pulse sourcing and ingredient mix rather than consumer fad duration. Use a pullback to build size, targeting a 1.5-2.0x upside/downside skew via stock or Jan-2026 calls.
• Pair trade long ADM / short GIS for a 3-6 month view: ADM captures upstream processing and ingredient economics, while GIS has more narrative risk if protein products fail to sustain repeat demand. Size for modest beta neutrality and a catalyst-driven rerating gap.
• If already long GIS, hedge with a short-dated call spread or trim into strength; the near-term upside is mostly sentiment-driven, while downside emerges quickly if retailer scan data disappoints over the next 1-2 quarters.
• Watch for confirmation in pulse acreage and ingredient procurement data over the next planting and earnings cycles; add to ADM only if margins improve without meaningful capex inflation, which would indicate real pricing power rather than transient demand.
• Avoid chasing small-cap “protein ingredient” names at this stage; the most asymmetric exposure is in scaled processors with distribution leverage, not in the most obvious consumer beneficiaries.